GeneDx Holdings Corp. (WGS)
| Market Cap | 236.76M |
| Revenue (ttm) | 234.69M |
| Net Income (ttm) | -548.98M |
| Shares Out | 798.25M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,520,494 |
| Open | 0.305 |
| Previous Close | 0.301 |
| Day's Range | 0.280 - 0.321 |
| 52-Week Range | 0.220 - 3.280 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 1.47 (+395.62%) |
| Earnings Date | May 11, 2023 |
About WGS
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holding... [Read more]
Financial Performance
In 2022, WGS's revenue was $234.69 million, an increase of 10.60% compared to the previous year's $212.20 million. Losses were -$548.98 million, 123.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for WGS stock is "Buy." The 12-month stock price forecast is $1.47, which is an increase of 395.62% from the latest price.
News
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
STAMFORD, Conn., March 20, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced ...
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing's role in shortening the diagnostic odyssey New research released at ACMG Annual Clinical ...
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management...
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Research illustrates company's progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth Research illustrates compa...
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process Research published in Nature Genetics underscores the role of genetic insig...
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A com...
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype disc...
Why Is GeneDx (WGS) Stock Down 8% Today?
GeneDx (NASDAQ: WGS) stock is taking a beating on Friday after the company revealed a proposed public stock offering. According to a press release, GeneDx intends to raise $150 million from the offer...
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a ...
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it i...